About HLA class II histocompatibility antigen, DR beta 4 chain
HLA class II histocompatibility antigen, DR beta 4 chain (HLA-DRB4) is a protein
from Homo sapiens identified by UniProt accession
P13762, 266 residues long.
MolForge cross-references it against 0 known binders and
103 disease associations.
Target properties
| Protein name | HLA class II histocompatibility antigen, DR beta 4 chain |
| UniProt accession | P13762 |
| Gene | HLA-DRB4 |
| Organism | Homo sapiens |
| Length | 266 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (103)
Diseases linked to this target (Open Targets).
- lymphoma · score 0.10
- chronic lymphocytic leukemia · score 0.08
- macrothrombocytopenia, isolated, 2, autosomal dominant · score 0.06
- thrombocytopenia 4 · score 0.05
- beta-thalassemia-X-linked thrombocytopenia syndrome · score 0.05
- congenital amegakaryocytic thrombocytopenia 1 · score 0.05
- autosomal dominant macrothrombocytopenia · score 0.05
- platelet-type bleeding disorder 9 · score 0.05
- autoimmune thrombocytopenic purpura · score 0.04
- transient myeloproliferative syndrome · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P13762-F1 | alphafold | PREDICTED | 87.05 | — |
Amino-acid sequence (266 residues)
MVCLKLPGGS CMAALTVTLT VLSSPLALAG DTQPRFLEQA KCECHFLNGT ERVWNLIRYI YNQEEYARYN SDLGEYQAVT ELGRPDAEYW NSQKDLLERR RAEVDTYCRY NYGVVESFTV QRRVQPKVTV YPSKTQPLQH HNLLVCSVNG FYPGSIEVRW FRNGQEEKAG VVSTGLIQNG DWTFQTLVML ETVPRSGEVY TCQVEHPSMM SPLTVQWSAR SESAQSKMLS GVGGFVLGLL FLGTGLFIYF RNQKGHSGLQ PTGLLS
Explore HLA class II histocompatibility antigen, DR beta 4 chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets